Home Blog Page 25

Japanese investors offered final opportunity to own at Chelsea Residences by DAMAC in Dubai

TOKYO, July 16, 2026 /PRNewswire/ — DAMAC Properties, the largest private real estate developer in the UAE and the Middle East, is set to unveil the sixth and final tower of Chelsea Residences by DAMAC at the Grand Ballroom, Mandarin Oriental on 17 July, following the exceptional sell-out performance of the first five towers.  

Chelsea Residences by DAMAC
Chelsea Residences by DAMAC

Developed in partnership with Chelsea Football Club, the landmark project has seen strong demand from investors and end-users, reinforcing the appeal of its waterfront location, branded residential proposition and lifestyle-led design. The launch of the final tower now presents the last opportunity to own an apartment within the world’s first football-branded residence.

Amira Sajwani, Managing Director, DAMAC Properties, said: “Chelsea Residences by DAMAC brings together an iconic global football brand, a prime waterfront setting and DAMAC’s signature approach to luxury living. With the launch of the final tower, investors have a rare opportunity to be part of a distinctive seafront community defined by panoramic sea views, wellness-led amenities and a lifestyle inspired by performance, leisure and resort-style living.”

As of 2025, Dubai leads the global branded residences market, with strong growth in transaction volumes of 26 percent YoY and growth in value of 51 percent YoY. Prices command a significant premium, going as much as 64 percent over non-branded units.[1]

Against this backdrop, Chelsea Residences by DAMAC offers a unique proposition, combining branded real estate, all sea-view apartments and curated amenities centered around football, wellness and resort-style living.

Chelsea Residences Tower C has a limited number of units available for sale, including one-bedroom, two-bedroom and three-bedroom residences. Prices start at JPY 112.9 million (USD 697,073), with sizes starting from 827 sq ft.

Apart from the unobstructed views of the sea and the Dubai skyline, residents also enjoy access to several amenities including the UAE’s only rooftop football pitch, a stunning blue-sand beach inspired by the team colours, a beach club and Athlete Training Centre.

Having delivered more than 50,000 homes and another 8,800 to be delivered in 2026 across Dubai, DAMAC is committed to creating lifestyle-driven communities that elevate everyday living into an immersive experience.

[1] https://www.cbre.ae/insights/figures/uae-branded-residences-report-2025 

Copyright Cases Dominate as Regulatory and Product Liability Challenges Emerge in the Q2 2026 J.S. Held AI Disputes Monitor

Content-creator litigation grows more sophisticated as courts are asked to weigh in on how AI regulation.

NEW YORK, July 16, 2026 /PRNewswire/ — Global consulting firm J.S. Held today releases the Q2 2026 J.S. Held AI Disputes Monitor, the firm’s proprietary dashboard tracking artificial intelligence (AI) litigation across technologies, industries, and jurisdictions. The Q2 2026 J.S. Held AI Disputes Monitor recorded 42 new AI-related lawsuits filed between April 1 and June 30, 2026, a 35% quarterly increase, as copyright and content-creator cases continued to dominate the docket and regulatory and product liability challenges emerged as new fronts in AI litigation. The total tracked dataset now stands at 426 cases, with year-to-date filings at 73 – 86% of the 2025 full-year total – putting 2026 on pace to move than double 2025 case filings.

Download the J.S. Held AI Disputes Monitor at https://oceantomo.com/js-held-ai-disputes-monitor/download/.
Download the J.S. Held AI Disputes Monitor at https://oceantomo.com/js-held-ai-disputes-monitor/download/.

Copyright and content-creator claims continue to comprise the majority of AI-related litigation, and the second-quarter dataset shows those cases becoming more sophisticated, further testing legal theory. At the same time, Q2 introduced new categories of dispute that were not meaningfully present in Q1, including constitutional and regulatory challenges to state AI laws, and product liability claims tied to generative AI outputs. Three developments define the quarter:

  1. Content-creator litigation is growing more sophisticated. Copyright and IP-related matters remain the largest category in the Monitor dataset, and Q2 filings show plaintiffs advancing more refined theories of harm, introducing claims tied to structured databases, music metadata, piracy-adjacent training data acquisition, and real-time competitive substitution.
  2. AI regulation itself has become the subject of litigation. The xAI challenge to Colorado’s AI Act (SB24-205), joined by a U.S. Department of Justice motion to intervene on April 24, 2026, is the first major test of whether state-level AI governance statutes can withstand constitutional scrutiny under the Equal Protection Clause. Enforcement of the law was suspended pending litigation and legislative activity. In a related first-of-its-kind action, Florida Attorney General James Uthmeier filed suit against OpenAI and Sam Altman, alleging that ChatGPT-related safety failures contributed to violent incidents and that OpenAI ignored safety warnings while prioritizing competitive positioning.
  3. Product liability and consumer protection claims tied to generative AI outputs are gaining momentum. Building on Gavalas v. Google (N.D. Cal., filed March 2026), a wrongful death action alleging that Google’s Gemini chatbot bypassed safety guardrails and generated responses instructing a user to take his own life, the trajectory established late in Q1 has continued into Q2 through a new wave of biometric privacy class actions targeting AI voice-model training. Together with the Q1 wrongful death and design-defect filings, these matters signal that platform design, safety guardrails, and model training practices are increasingly being tested under product liability, consumer protection, and biometric privacy theories.

What Has Changed Since Q1 2026

Dimension

Q1 2026

Q2 2026

New filings in quarter

31

42 (+35%)

Dominant category

Copyright and content-creator claims, with first
signals of AI-driven insurance disputes

Copyright and content-creator claims still dominant; 

regulatory challenges and product liability emerge
as new fronts

Notable “first”

First signals of AI-driven insurance disputes

First constitutional challenge to a state AI statute
suit against a foundation model developer; first

wave of BIPA-style class actions targeting AI

voice-model training

The second-quarter snapshot reinforces a central theme of the Monitor: AI litigation is becoming a cross-jurisdictional, cross-sector, and cross-regulatory phenomenon that will shape how organizations govern, disclose, and deploy AI for years to come.

A More Complex Expert Landscape Emerges in Q2
“Litigation surrounding Colorado’s AI Act highlights an important shift in the AI landscape,” said J. Scott Womack, Senior Director in the Office of the Chief Intellectual Property Officer at J.S. Held and head of the AI Disputes Monitor data analysis team. “Courts are now being asked to weigh in on how AI should be regulated, a distinct question from whether specific AI uses cross legal lines. Cases like Colorado’s are an important part of how the practical limits of AI governance are tested, with implications for organizations, policymakers, and legal practitioners.”

The Q2 update also underscores how quickly the technical and financial questions in AI disputes are expanding to involve synthetic content, model provenance, training-data licensing, and platform-level safety design.  These matters surface evidentiary questions that require reconstruction to demonstrate how AI systems behaved during the period of harm.

“AI-related disputes require both technical evidence and financial analysis. How was the system built? How does it use copyrighted or licensed material? What is that use worth?” said James E. Malackowski, CPA, CLP, Chief Intellectual Property Officer at J.S. Held. “The Q2 copyright filings underscore how central valuation, licensing benchmarks, and IP cost analysis have become to AI litigation. As theories of harm grow more refined, from real-time competitive substitution to structured-database scraping, the economic questions are becoming more robust, and courts will need well supported answers.”

As the product liability front takes shape, questions of user behavior, safety guardrails, and foreseeable misuse are moving to the center of AI-related disputes. Unlike traditional product liability matters, generative AI systems produce outputs that are shaped in real time by user inputs — making the interaction between design intent, safety controls, and user experience critical to establishing what the system did, why it did it, and whether the harm was reasonably foreseeable.

“AI-related product liability disputes require a rigorous human factors lens,” said Dr. Blake Pellman, PhD, Senior User Experience Researcher at J.S. Held. “Like any other kind of product, one needs to understand whether the system was being used for its intended purpose, how the system communicated the ways it should and should not be used, and what safeguards were in place to protect against foreseeable misuse. However, many AI products do not conform to traditional design principles, and this may expose companies to a greater risk of liability. Applying structured user research and human factors research to these questions helps clients, courts, and juries evaluate what happened and whether it was foreseeable and preventable.”

The forensic dimension of these matters is also significant. Wrongful death and design-defect, and biometric class actions involving generative AI systems raise evidentiary questions about how the underlying technology was built and deployed and often require structured reconstruction to answer them.

“AI disputes exist at the intersection of three inseparable domains — technical, financial, and evidentiary — and the Q2 docket makes that more visible than any prior quarter,” said JP Brennan, Senior Managing Director at J.S. Held. “Our work focuses on helping clients understand and explain how these systems operate in real-world contexts. We apply structured forensic methods, including system log reconstruction, prompt replay, model version analysis, and data provenance review, to support investigations and testimony in matters where the underlying technology is often the central evidentiary question.”

To explore the full set of Q2 findings, download the latest edition of the J.S. Held AI Disputes Monitor.

About J.S. Held
J.S. Held is a global consulting firm that combines technical, scientific, financial, and strategic expertise to advise clients seeking to realize value and mitigate risk. Our professionals serve as trusted advisors to organizations facing high-stakes matters demanding urgent attention, staunch integrity, proven experience, clear-cut analysis, and an understanding of both tangible and intangible assets. The firm provides a comprehensive suite of services, products, and data that enable clients to navigate complex, contentious, and often catastrophic situations.

More than 1,500 professionals serve organizations across six continents, including 84% of the Global 200 Law Firms, 75% of the Forbes Top 20 Insurance Companies (90% of the NAIC Top 50 Property & Casualty Insurers), and 71% of Fortune 100 Companies.

J.S. Held, its affiliates and subsidiaries are not certified public accounting firm(s) and do not provide audit, attest, or any other public accounting services. J.S. Held is not a law firm and does not provide legal advice. Securities offered through PM Securities, LLC, d/b/a Phoenix IB or Ocean Tomo Investments, a part of J.S. Held, member FINRA/SIPC. All rights reserved.

Contact: Kristi L. Stathis | Global Public Relations | +1 786 833 4864 | Kristi.Stathis@jsheld.com

First Patients Dosed in OPTIMAL-e Trial for Earlier Stage Prostate Cancer

  • First patients dosed in OPTIMAL-e[1] Phase 2 study evaluating TLX597-Tx for metastatic hormone-sensitive prostate cancer at St Vincent’s Hospital Sydney.
  • OPTIMAL-e will evaluate TLX597-Tx in earlier prostate cancer treatment setting, building on the OPTIMAL-PSMA[2] study which recently completed patient enrollment.
  • TLX597-Tx is Telix’s next generation PSMA[3]-targeting small molecule radioligand therapy candidate designed to improve efficacy and quality of life in earlier-stage prostate cancer.

MELBOURNE, Australia and INDIANAPOLIS, July 16, 2026 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) and St Vincent’s Hospital today announced that the first patients have been dosed with TLX597-Tx (177Lu-DOTA-HYNIC-panPSMA) in the OPTIMAL-e trial, led by Professor Louise Emmett for patients with metastatic hormone-sensitive prostate cancer (mHSPC) at St Vincent’s Hospital in Sydney, Australia.

OPTIMAL-e is a single-arm, open-label trial, evaluating adaptive-dosed TLX597-Tx in combination with androgen deprivation therapy (ADT) and an androgen receptor pathway inhibitor (ARPI) in men with mHSPC. The study will evaluate the impact of TLX597-Tx on PSA[4] response rate in an earlier treatment setting, assessing its potential to improve both the depth and durability of PSA response, while further evaluating the safety of dose intensification.

TLX597-Tx is a highly-targeted next generation small molecule RLT[5] designed to improve efficacy and quality of life in earlier-stage metastatic prostate cancer. It has demonstrated a favorable biodistribution and dosimetry profile in prior studies including OPTIMAL-PSMA[6], suggesting low exposure to salivary glands and the kidneys, the healthy organs of concern with PSMA RLT, and high uptake in PSMA-expressing tumors.

Louise Emmett, MD, Director of Theranostics and Nuclear Medicine, St. Vincent’s Hospital, and Lead Investigator of the OPTIMAL-e study, said, “I am excited to lead the OPTIMAL-e trial, which is evaluating an adaptive treatment approach designed to tailor therapy to each patient’s response. By using PSMA-PET[7] imaging and PSA measurements to monitor disease burden, treatment can be continued when the PSMA target persists, and paused when there is a significant reduction in tumor burden. This individualized strategy aims to maintain disease control while minimizing unnecessary treatment exposure, with the potential to keep patients in a low-volume disease state for longer and support quality of life. The findings from OPTIMAL-e may help shape future treatment strategies and advance precision medicine for men living with prostate cancer.”

David N. Cade, MD, Group Chief Medical Officer, Telix, said, “The initiation of OPTIMAL-e marks an important evolution of PSMA-targeted radioligand therapy for earlier metastatic prostate cancer, where maintaining quality of life is paramount. While the currently approved radioligand therapy has demonstrated a modest improvement in overall survival in advanced-stage disease, we believe earlier intervention may offer the potential to further improve outcomes and prolong quality of life for patients.”

TLX597-Tx has not received marketing authorization in any jurisdiction.

About OPTIMAL-e

OPTIMAL-e is a Phase 2, non-randomized pilot study evaluating adaptive-dosed TLX597-Tx (177Lu-DOTA-HYNIC-panPSMA) in combination with ADT and an ARPI in patients with metastatic hormone-sensitive prostate cancer (mHSPC). Adaptive dosing of 177-Lu-PSMA is the concept of only treating if the PSMA target is persistent, while pausing treatment if there is a marked reduction in the tumor target, with re-treatment at first confirmed PSA rise (once the target has returned). The study is investigating whether intensified, response-adapted PSMA-targeted radioligand therapy can deepen responses, improve disease control and enable treatment pauses for selected patients based on PSMA-PET imaging and PSA outcomes.

TLX597-Tx is being developed alongside TLX591-Tx (lutetium-177 (177Lu) rosopatamab tetraxetan), Telix’s lead antibody-based prostate cancer therapy candidate, currently the subject of the Phase 3 ProstACT Global[8] trial in mCRPC[9], which is actively dosing patients in jurisdictions with regulatory approval. TLX591-Tx and TLX597-Tx exhibit complementary modes-of-action, suggesting the potential for distinct applications in mCRPC and mHSPC settings as part of Telix’s portfolio approach to treating prostate cancer.

About Telix Pharmaceuticals Limited

Telix Pharmaceuticals (ASX: TLX, NASDAQ: TLX) is a commercial-stage global radiopharmaceutical company, advancing targeted theranostics to improve outcomes for people with cancer across the patient journey. Theranostics pairs a precision diagnostic with a targeted therapy to both diagnose and treat disease. 

Telix’s commercial franchise is anchored by its prostate cancer imaging portfolio: Illuccix® (kit for the preparation of gallium-68 gozetotide injection), commercially available in 22 countries including the U.S. and Gozellix® (kit for the preparation of gallium-68 gozetotide injection), Telix’s next-generation PSMA-PET imaging agent approved by the U.S. FDA. The Company’s late-stage therapeutic pipeline includes three assets in pivotal-stage trials – TLX591-Tx (lutetium-177 (177Lu) rosopatamab tetraxetan) in prostate cancer, TLX101-Tx (131I-iodofalan) in recurrent glioblastoma, TLX250-Tx (177Lu-girentuximab) in kidney cancer, complemented by a deep pipeline of next generation assets.

Telix is headquartered in Melbourne, Australia, with operations across North America, Europe, Latin America and Asia-Pacific. For more information, visit www.telixpharma.com or follow Telix on LinkedIn, X and Facebook.

Telix Contacts

Investor Relations

Annie Kasparian
annie.kasparian@telixpharma.com

 

Charlene Jaw                        
charlene.jaw@telixpharma.com

Media

Eliza Schleifstein

917.763.8106 (Mobile)

Eliza@schleifsteinpr.com

Legal Notices

Cautionary Statement Regarding Forward-Looking Statements. 
 

You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website.

The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification.  To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement.

This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “believe”, “outlook”, “forecast” and “guidance”, or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress, completion and results of Telix’s preclinical and clinical trials, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix’s product candidates, manufacturing activities and product marketing activities; Telix’s sales, marketing and distribution and manufacturing capabilities and strategies; the commercialization of Telix’s product candidates, if or when they have been approved; Telix’s ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating to Telix’s competitors and industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic conditions on Telix’s business, including as a result of war or other geopolitical conflicts; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.

Trademarks and Trade Names. All trademarks and trade names referenced in this press release are the property of Telix Pharmaceuticals Limited (Telix) or, where applicable, the property of their respective owners. For convenience, trademarks and trade names may appear without the ® or ™ symbols. Such omissions are not intended to indicate any waiver of rights by Telix or the respective owners. Trademark registration status may vary from country to country. Telix does not intend the use or display of any third-party trademarks or trade names to imply any affiliation with, endorsement by, or sponsorship from those third parties.

©2026 Telix Pharmaceuticals Limited. All rights reserved.

[1] Australian New Zealand Clinical Trials Registry ID: ACTRN12626000034336.

[2] Australian New Zealand Clinical Trials Registry ID: ACTRN12625000971437.

[3] Prostate-specific membrane antigen.

[4] Prostate-specific antigen.

[5] Radioligand therapy.

[6] Telix media release April 30, 2026.

[7] Imaging of prostate-specific membrane antigen with positron emission tomography.

[8] ClinicalTrials.gov ID: NCT06520345.

[9] Metastatic castration-resistant prostate cancer.

 

Webull Corporation Reports June 2026 Operating Data

ST. PETERSBURG, Fla., July 16, 2026 /PRNewswire/ — Webull Corporation (NASDAQ: BULL) today reported select monthly operating data for June 2026.

  • Registered Users at the end of June were 28.2 million (up approximately 200 thousand from the end of May 2026, and up approximately 3.3 million year-over-year).
  • Funded Accounts at the end of June were 5.1 million (unchanged from the end of May 2026, and up approximately 400 thousand year-over-year).[1]
  • Customer Assets at the end of June were $28.5 billion (down 3% from the end of May 2026, and up 79% year-over-year).
  • Net Deposits were $800 million in June (up 60% from the end of May 2026, and up 60% year-over-year).

[1] In the second quarter of 2026, we added 132 thousand new funded accounts, and 22 thousand net new funded accounts. During this time, we closed 72 thousand accounts through escheatment.

Trading Activity in June:

  • Equity Notional Trading Volume was $105.8 billion (up 21% from the end of May 2026, and up 88% year-over-year). Average daily volumes (“ADVs”) were $5 billion (up 15% from May 2026, and up 79% year-over-year).
  • Options Contracts Volume was 89.4 million (up 43% from the end of May 2026, and up 112% year-over-year). ADVs were 4.3 million contracts (up 36% from May 2026, and up 102% year-over-year).
  • Equities DARTs were 1.3 million (up 57% from the end of May 2026, and up 110% year-over-year).
  • Options DARTs were 655 thousand (up 37% from the end of May 2026, and up 91% year-over-year).
  • Other DARTs were 136 thousand (up 11% from the end of May 2026, and up 167% year-over-year).

Interest-Earning Asset Balances at the end of June:

  • Client Bank Deposits were at $3.9 billion (down 13% from the end of May 2026, and up 7% year-over-year).
  • Margin balances were at $990 million (up 17% from the end of May 2026, and up 110% year-over-year).

Monthly Metrics Report (Unaudited)
Webull Corporation & Consolidated Subsidiaries
June 2026

The following table presents certain of our unaudited financial and operational metrics by month.

Operational Metrics

2025-06

2025-07

2025-08

2025-09

2025-10

2025-11

2025-12

2026-01

2026-02

2026-03

2026-04

2026-05

2026-06

Registered Users (in millions)

24.9

25.1

25.4

25.9

26.2

26.5

26.8

27.1

27.3

27.6

27.8

28.0

28.2

Funded Accounts (in millions)

4.7

4.7

4.8

4.9

5.0

5.1

5.0

5.1

5.1

5.1

5.1

5.1

5.1

Customer Assets ($ in billions)

$15.9

$16.9

$18.0

$21.2

$24.4

$       23.3

$24.6

$25.4

$24.9

$24.0

$26.8

$ 29.3

$28.5

Net Deposits ($ in billions)

$ 0.5

$0.6

$0.9

$ 0.7

$ 1.7

$         1.0

$1.2

$0.9

$0.6

$0.6

$ 0.3

$ 0.5

$0.8

Equity Notional Volume ($ in billions)

$56.4

$67.9

$63.5

$72.6

$93.2

$       72.1

$74.0

$87.2

$76.4

$96.9

$85.4

$87.7

$105.8

Options Contracts Volume (in millions)

42.1

47.1

48.2

51.7

58.7

46.0

49.5

52.0

50.3

56.4

60.7

62.7

89.4

DARTs (in thousands) :

   Equities

639

683

657

766

850

701

616

830

736

733

756

856

1,341

   Options

343

334

349

369

394

385

352

409

431

418

442

479

655

   Others

51

47

48

55

95

116

92

119

128

134

117

123

136

Interest Earning Asset Balances(1) ($ in millions):

   Client Bank Deposits(2)

$3,608

$3,484

$3,576

$ 3,854

$3,976

$     3,929

$4,268

$4,126

$3,968

$3,892

$4,258

$4,472

$3,872

   Margin(3)

$471

$568

$598

$ 626

$707

$        659

$690

$794

$761

$ 750

$ 776

$849

$990

(1) Represents month-end balances.

(2) Balance includes cash and cash equivalents segregated under federal and foreign regulations, customers’ cash that is participating in our off-balance sheet cash sweep program, and cash of our platform users who are on a fully introduced basis with Apex Clearing.

(3) Balance includes both our on-balance sheet margin loans and the off-balance sheet margin loans of our platform users’ that are administered on a fully-introduced basis with Apex Clearing.

Disclosures

Monthly Metrics Report

Monthly Metrics Reports (“Report”) provide certain limited purpose monthly statistical and operational results of Webull Corporation and its consolidated subsidiaries (“We” or “Webull”). This Report is presented without commentary and should be read together with our most recent quarterly and annual results and U.S. Securities and Exchange Commission (“SEC”) filings on Forms 6-K and 20-F, which are available on the SEC Filings tab of our Investor Relations website at www.webullcorp.com/investor-relations/sec.

Statement regarding unaudited financial and operational information

The unaudited financial and operational information included in this Report is subject to potential adjustments and is based on information available to management as of the date this Report is prepared. Potential adjustments to operational and consolidated financial information may be identified in connection with Webull’s preparation of subsequent financial statements or its year-end audit. Information may also be presented differently in future filings or disclosures. This could result in differences from the unaudited or other historical operational and financial information included herein.

Definitions

“Average daily volumes” refers to the total trading volume in a given period divided by the applicable number of trading days in the said period.

“Registered Users” refers to those users who have registered on our platform but not necessarily have opened a brokerage account with one of our licensed broker-dealers. Growth in our registered users provides insight as to the popularity of the Webull App. While we do not generate revenue from registered users who do not have brokerage accounts with us, registering an account on the Webull App is the first step toward opening and funding a brokerage account with us.

“Funded Accounts” refers to Webull brokerage accounts into which the customer has made an initial deposit or money transfer, of any amount, whose account balance (which is measured as the fair value of assets in the customer’s account less the amount due from the customer) has not dropped to or below zero for 45 consecutive calendar days as of the record date. Funded accounts reflect unique customers, and multiple funded accounts by a single customer are counted as one funded account. Growth in our funded accounts provides insight as to the effectiveness of our marketing efforts and our ability to acquire monetizable customers. Funded accounts are positively correlated with, but are not determinative, of customer assets, trading volumes, and revenue.

“Customer Assets” refers to the sum of the fair value of all equities, ETFs, options, warrants, futures, digital assets and cash held by customers in their Webull brokerage accounts, net of customer margin balances, as of the record date. While customer assets are significantly impacted by mark-to-market valuations of customers’ investments and digital holdings, we consider customer assets an important metric as growth in customer assets generally leads to an increase in trading volumes and revenue.

“Net Deposits” refers to all cash deposits and assets transfers received from customers, net of reversals, customer cash withdrawals, and assets transferred out of our platform. 

“Equity Notional Volume” refers to the aggregate dollar value (purchase price or sale price as applicable) of trades executed over a specified period of time. Equity notional volume directly drives our equities trading revenue, as we earn payment for order flow or commissions for customers’ equities trades based on a percentage of notional value. However, equity notional volume is highly sensitive to market conditions in the short-term which makes predicting our equity trading revenue with precision difficult.

“Options Contract Volume” refers to the total number of options contracts bought or sold over a specified period of time. Options contracts volume directly drives our options trading revenue, as we earn payment for order flow or commissions for customers’ options trades on a per contract basis. However, options contracts volume is highly sensitive to market conditions in the short-term, which makes predicting our options trading revenue with precision difficult.

“DARTs” refers to daily average revenue trades, which is the number of customer trades executed during a given period divided by the number of trading days in that period. DARTs provide us information on how active our customers trade. A limitation of this metric is that it does not capture the size of the trade and revenue per trade varies significantly depending on size and type of trades.

About Webull Corporation

Webull Corporation (NASDAQ: BULL) owns and operates Webull, a leading digital investment platform built on next-generation global infrastructure and AI technologies. Through its global network of licensed brokerages, Webull offers investment services in 16 markets across North America, Asia Pacific, Europe, Africa, and Latin America. Webull serves more than 28 million registered users globally, providing retail and institutional investors with 24/7 access to global financial markets. Users can put investment strategies to work by trading global stocks, ETFs, options, futures, fractional shares, and digital assets through Webull’s trading platform, which seamlessly integrates market data and information, its user community, and investor education resources. Learn more at www.webullcorp.com.

Media Contact:
5W Public Relations
Abigail Rush
Webull@5WPR.com
(212) 999-5585

IR Contact:
ir@webullcorp.com

EaseUS Releases the Summer Travel Data Protection Guide Featuring SSR and DVR Technologies for Multi-Device Photo and Video Recovery

NEW YORK, July 16, 2026 /PRNewswire/ — As the summer travel season reaches its peak, more travelers are using action cameras, drones, and mirrorless cameras to capture 4K/8K videos and RAW photos. Most memory card data loss incidents are caused not by physical damage, but by file system errors, accidental deletion, or interrupted recording and writing processes. For long video recordings, file fragmentation can make data recovery more challenging.

Summer outdoor conditions add further risks. Humidity, extreme heat, and constant vibrations during travel can affect storage stability, especially for users managing multiple devices. In many cases, cloud backups alone are not enough to protect valuable footage.

What Are the Common Misconceptions and Risks in Mass Image Storage and Backup Across Cameras and Storage Devices?

Many photography enthusiasts mistakenly believe that enabling cloud services guarantees the safety of their footage. Camera cloud services often impose device-binding restrictions, and the large RAW files generated by drones and mirrorless cameras can quickly exhaust cloud storage capacity. In remote areas with poor connectivity, automatic data synchronization fails, leaving raw footage stored solely on memory cards that lack robust protection.

High-frame-rate recording fragments video data and scatters file metadata; aerial footage involves split audio and video data packets that standard recovery tools cannot reassemble, meaning that even if the data is retrieved, the recovered videos won’t play.

Furthermore, common operational errors significantly increase the risk of file corruption: deleting footage directly within the camera, filling the memory card to over 90% capacity, or pairing high-performance recording equipment with slow memory cards.

How Photographers Can Prevent Memory Card Data Loss Through Backup and Recovery?

Adopting a dual-protection strategy that combines proactive storage management protocols with advanced recovery technologies can significantly reduce the risk of losing video footage during summer travels.

First, outdoor creators should establish a multi-medium redundant backup architecture: simultaneously saving footage to both rugged, portable SSDs and separate memory cards to prevent data loss caused by the failure of a single storage medium.

Second, in the event of data loss, reliable memory card recovery software should be used promptly to retrieve valuable data. The EaseUS data recovery team has developed proprietary hybrid technologies: SSR (Smart Sector Reconstruction) and DVR (Deep Video Reconstruction). SSR scans damaged memory cards from drones or action cameras to locate fragmented data markers, while DVR analyzes the specific encoding rules of the camera to reassemble broken video frames, enabling the lossless recovery of complete, playable videos. Compared to traditional algorithms, this solution increases the success rate of recovering travel footage by 27%.

EaseUS SSR-DVR Integrated Data Recovery Tool to Recover Travel Photos and Videos Across Multiple Devices

As a global leader in lightweight data recovery, EaseUS has spent two decades advancing image and video repair technology, creating this integrated SSR and DVR repair tool specifically for photographers who travel with multiple devices.

This technology is embedded within the EaseUS Data Recovery Wizard software. It supports all mainstream drone, action camera, and mirrorless camera formats, features one-click scanning, and is compatible with Windows and macOS environments for mobile outdoor workflows.

The brand continuously updates its algorithm database to keep pace with new camera firmware released each summer, ensuring efficient handling of complex file fragmentation issues arising from 8K ultra-high-definition recording and high-frame-rate slow-motion capture.

About EaseUS Software

EaseUS provides professional IT solutions for home, education, and SMB users in data recovery, backup, system optimization, partition management, and multimedia on Windows, Mac, iOS, and Android. Founded in 2004, the company now serves over 100,000,000 users worldwide. For more information, visit http://www.easeus.com.

China Pharma Holdings, Inc. States It Knows of No Events That Could Have Caused Unusual Market Activity

HAIKOU, China, July 16, 2026 /PRNewswire/ — China Pharma Holdings, Inc. (NYSE American: CPHI) (“China Pharma” or the “Company”), a fully-integrated specialty pharmaceuticals company in China, today announced that, in view of the unusual market activity in the common stock of China Pharma on July 10, 13, and 15, 2026, the NYSE American has contacted the Company in accordance with its usual practice. The Company stated that, while its policy generally is not to comment on unusual market activity, it is not aware of any material nonpublic information or business developments that have not been publicly disclosed that would account for the recent trading activity.

About China Pharma Holdings, Inc.

China Pharma Holdings, Inc. is a specialty pharmaceutical company that develops, manufactures and markets a diversified portfolio of products focused on conditions with a high incidence and high mortality rates in China, including cardiovascular, CNS, infectious, and digestive diseases. The Company’s cost-effective, high-margin business model is driven by market demand and supported by eight scalable GMP-certified product lines covering the major dosage forms. In addition, the Company has a broad and expanding nationwide distribution network across all major cities and provinces in China. The Company’s wholly-owned subsidiary, Hainan Helpson Medical & Biotechnology Co., Ltd., is located in Haikou City, Hainan Province. For more information about China Pharma Holdings, Inc., please visit http://www.chinapharmaholdings.com. The Company routinely posts important information on its website.

Safe Harbor Statement 

Certain statements in this press release constitute forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Any statements set forth above that are not historical facts are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements, which may include, but are not limited to, such factors as the achievability of financial guidance, success of new product development, unanticipated changes in product demand, increased competition, downturns in the Chinese economy, uncompetitive levels of research and development, and other information detailed from time to time in the Company’s filings and future filings with the United States Securities and Exchange Commission. The forward-looking statements made herein speak only as of the date of this press release and the Company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the Company’s expectations except as required by applicable law or regulation.

Contact:

China Pharma Holdings, Inc. 
Phone: +86-898-6681-1730 (China)
Email: hps@chinapharmaholdings.com

LiveLarge Reveals Flagship L-Space, Showcasing an AI-Powered Adaptive Living Environment

AI in living spaces evolves from an aftermarket add-on to an embedded intelligence layer.

LOS ANGELES, , July 16, 2026 /PRNewswire/ — LiveLarge Home Inc. (“LiveLarge” or the “Company”) today announced its Flagship L-Space, introducing a new category of AI-native living spaces designed to proactively adapt to users’ activities, preferences, and personalized settings in real time. Incorporating Space AI, the Flagship L-Space represents LiveLarge’s long-term vision to infuse artificial intelligence into the home, creating spaces that empower their occupants.

LiveLarge Home Inc. Flagship L-Space
LiveLarge Home Inc. Flagship L-Space

In NVIDIA’s June 24 Annual Stockholders Meeting, Nvidia chief executive officer Jensen Huang described physical AI as the “next wave of growth” for the company, defining it as “agentic AI in the real world.” While this statement was directed at industrial applications such as robotics and manufacturing, its potential far exceeds those sectors. For example, the home automation AI market is projected to grow from US$34.57 billion in 2026 to US$97.05 billion by 2030[1].

In line with the development, the LiveLarge Flagship L-Space is the Company’s first demonstration of an AI-native living space, a new product category where intelligence is embedded directly into buildings. By using AI that predictively orchestrates intelligent sensors and subsystems inside the home, LiveLarge aims to personalize spaces that can adapt to the user’s mood in real time and learn their preferences, creating environments that connect with their emotions.

Space AI enables AI intelligence inside the home

Recent advances in AI have largely centered on large language models and robotics, while its application in living spaces remains untapped despite its vast potential to transform how people live and work.

Before the advent of AI, users relied on smart home devices to automate daily routines. However, these devices often worked in isolation, creating more stress in managing them. Also, their functions were often reactive, rather than proactive.

“Smart home setups have been stuck in an aftermarket device model for too long,” said Endong Zhang, Founder and CEO of LiveLarge Home Inc. “We believe the next generation of home intelligence needs a built-in system layer that can unify space, devices, sensors, AI, and user context. L-Space is where we start–a controllable and deliverable space to integrate and improve that experience over time.”

Now with Space AI, LiveLarge aims to bridge this gap, creating living spaces that can anticipate the preferences of every family member and optimize their surroundings to suit the situation.

At the center of Space AI is Lila, LiveLarge’s smart assistant that’s always ready to help. Learning the users’ individual preferences and storing them in long-term memory, Lila orchestrates the Flagship L-Space’s various modules–the 5.1 surround sound system, air circulation, 4K short-throw projector and more–as a cohesive system. By interpreting user preferences and tasks, Lila can predictively adjust interior conditions with minimal input from the user.

The Flagship L-Space is designed with privacy and user control in mind, with core modules capable of operating locally and user preferences stored locally where applicable.

As a premium standalone space, the Flagship L-Space is designed to be installed faster than conventional site-built structures. Completion time varies depending on site conditions, permitting requirements, and local regulations.

“U.S. customers are not asking for more devices to manage. They are asking for better spaces,” said Thalia Cheng, President of LiveLarge, “L-Space turns that need into a private, flexible product experience for work, wellness, creativity, and everyday life.”

Availability

The LiveLarge Flagship L-Space will be available in California on a made-to-order basis.

About LiveLarge

LiveLarge Home Inc. is a California-based company building premium space products and AI-enabled living environments for the future of home. With experience across prefab homes, ADUs, and standalone lifestyle spaces, LiveLarge combines design, construction, manufacturing, and emerging AI capabilities to create more adaptive, human-centered environments for modern living.

[1](2026, February 1). AI in Home Automation Market Report 2026. The Business Research Company; The Business Research Company. https://www.thebusinessresearchcompany.com/report/artificial-intelligence-ai-in-home-automation-global-market-report 

EnGenius Strengthens Cloud-Managed Layer 3 Switching Portfolio with New Core and Aggregation Switches

New switches support growing SMB, MSP, and enterprise network requirements with 10G aggregation, 100G backbone scalability, interoperable Layer 3 routing, resilient design, and cloud visibility with local control. 

COSTA MESA, Calif., July 16, 2026 /PRNewswire/ — EnGenius today announced a new lineup of cloud-managed Layer 3 switches purpose-built for enterprise, system integrator, VAR, and MSP networks.

EnGenius Strengthens Cloud-Managed Layer 3 Switching Portfolio
EnGenius Strengthens Cloud-Managed Layer 3 Switching Portfolio

The new series includes three models: the enterprise-class ECS8830F and ECS8854F, along with the ECS6824F for SMB core, branch, and managed service provider (MSP) deployments. Together, the EnGenius Cloud-Managed Layer 3 Switches help organizations modernize network infrastructure with high-density 10G aggregation, 100G backbone connectivity, advanced Layer 3 routing, resilient design, and centralized cloud-based management across access, aggregation, and core.

As enterprise networks support more Wi-Fi 7 deployments, video analytics, edge applications, virtualized workloads, distributed services, and high-bandwidth east-west traffic, the network core can no longer be treated as a simple aggregation point. Modern IT teams need a core architecture that supports scalable routing, secure segmentation, operational resilience, and clear visibility across the network.

Enterprise-Class Core and Aggregation: ECS8830F and ECS8854F

The ECS8830F and ECS8854F are built for enterprise core and aggregation networks that require advanced Layer 3 routing, high availability, and scalable network operations.

The ECS8830F provides 24 × 10G SFP+ ports and 6 × 100G QSFP28 uplinks with up to 1.68 Tbps switching capacity, while the ECS8854F expands scale with 48 × 10G SFP+ ports and 6 × 100G QSFP28 uplinks with up to 2.16 Tbps switching capacity. Both platforms support up to 600 Mpps forwarding performance and wire-speed throughput to support high-performance enterprise network environments.

To support scalable network architectures, the platforms combine advanced Layer 3 routing and network virtualization capabilities, including OSPFv2/v3, BGP/BGP4+, IS-IS, ECMP, VRRP, Policy-Based Routing (PBR), BFD, and VXLAN EVPN. These capabilities enable resilient traffic forwarding, network segmentation, high-availability designs, and scalable multi-site connectivity while supporting interoperability across existing infrastructure investments. The result is simplified network operations, improved resiliency, and the flexibility to scale enterprise networks as business requirements evolve.

For maximum network resiliency and business continuity, the platforms support MC-LAG and VSF, along with 1+1 redundant hot-swappable power supplies and 3+1 redundant hot-swappable fan modules. This architecture eliminates single points of failure, enables seamless failover, and maintains service continuity, reducing service disruption and simplifying maintenance for enterprise network environments.

The series also supports a hybrid operational model. IT teams can use EnGenius Cloud for centralized visibility and monitoring while retaining local access through Web UI, CLI, SNMP, NETCONF, syslog, and related operational tools for configuration, troubleshooting, and day-to-day administration.

Right-Sized 10G Layer 3 Core for SMB and MSP Networks: ECS6824F

The ECS6824F delivers a high-performance 10G Layer 3 fiber core to growing SMBs, branch networks, and MSP-managed environments seeking greater scalability, security, and network control without the complexity of enterprise-class core platforms.

The 1U switch provides 24 × 10G SFP+ ports and 480 Gbps switching capacity, with Static Routing, RIP, and OSPFv2/v3 to help organizations segment departments, applications, surveillance systems, guest networks, and server zones more effectively.

For video-centric and multicast environments, the ECS6824F includes IGMP and MLD support to improve multicast traffic efficiency for IPTV and IP surveillance deployments. It also integrates core-layer security controls, including 802.1X authentication, ACLs, DHCP Snooping, IP Source Guard, ARP protection, Port Security, Storm Control, and DoS protection.

Dual internal power supplies add hardware resiliency, while EnGenius Cloud delivers centralized visibility, monitoring, and management for IT teams and MSPs.

Extending the EnGenius Portfolio from Access to Core

“This launch represents a significant expansion of the EnGenius networking portfolio and marks an important step in extending our cloud-managed platform from access to core,” said Roger Liu, CEO of EnGenius. “As enterprise networks continue to evolve, organizations need switching solutions that deliver greater scalability, resiliency, and operational simplicity. With this new series, we are providing a stronger foundation to support modern enterprise and managed network deployments.”

With the introduction of the new series, EnGenius extends its cloud-managed switching portfolio to address enterprise core, aggregation, and SMB core deployments. Together with EnGenius Cloud, the new switches combine cloud visibility with local control, enabling organizations, system integrators, VARs, and MSPs to deploy and manage networks through a consistent operational experience as their infrastructure grows.

Learn more about Cloud-Managed Layer 3 Switching Portfolio

ECS6824F: https://www.engeniustech.com/ecs6824f-cloud-managed-layer-3-fiber-switch.html
ECS8830F: https://www.engeniustech.com/ecs8830f-layer-3-stackable-switch.html
ECS8854F: https://www.engeniustech.com/ecs8854f-48-port-stackable-layer-3-switch.html

About EnGenius

EnGenius Technologies is a global leader in cloud-driven networking solutions, with over 25 years of expertise in developing and delivering innovative, user-friendly hardware and software. The company’s secure, cloud-managed ecosystem — including wireless access points, network switches, VPN Firewalls, AI cameras, AI-powered network video systems, and power distribution units — empowers businesses across industries such as enterprise, education, healthcare, retail, and logistics to build high-performance, reliable, and scalable network infrastructures.